Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy
Publication Date: 11/24/2023
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
Publication Date: 3/29/2023
Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201
Publication Date: 10/12/2022
Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas.
Cancers 2022, 14, 3037.
Publication Date: 6/21/2022
Synthetic Antibody Rallies Immune Cells Against Ovarian Cancer
Publication Date: 8/25/2020
Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer
Publication Date: 6/19/2020
Results of Precision Biologics Phase 2 Colorectal Cancer Study Published in Clinical Cancer Research
Publication Date: 4/17/2020
The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway
Publication Date: 1/2020
Rationale, discovery and clinical development of NEO-201
Publication Date: 11/2019
An IL-15 Superagonist, AL T-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells
Publication Date: 3/2019
Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas
Publication Date: 1/2018
Neoantigens in the immuno-oncology space
Publication Date: 10/2017
A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer
Publication Date: 7/2016
Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models
Publication Date: 3/2013